User login
Key clinical point: Multi-agent adjuvant chemotherapy (MAC) offers a survival benefit over single-agent adjuvant chemotherapy (SAC) in patients with stage III colon cancer (CC) aged 70-75 years, but not for older patients.
Major finding: MAC vs. SAC was associated with a survival benefit in patients aged 70-75 years (hazard ratio [HR] 0.81; P < .001), but not in those aged 76-80 (HR 0.90; P = .051), 81-85 (HR 0.97; P = .637), or 86-90+ (HR 0.95; P = .691) years.
Study details: This retrospective, age group-based study included 20,257 patients aged ≥70 years with stage III CC who received either SAC (n = 7334) or MAC (n = 12,923).
Disclosures: The study was supported by the Winship Research Informatics Shared Resource of Winship Cancer Institute of Emory University and US National Institutes of Health/National Cancer Institute. The authors declared no conflicts of interest.
Source: Khalil L et al. Survival outcomes of adjuvant chemotherapy in elderly patients with stage III colon cancer. Oncologist. 2022 (Jun 1). Doi: 10.1093/oncolo/oyac082
Key clinical point: Multi-agent adjuvant chemotherapy (MAC) offers a survival benefit over single-agent adjuvant chemotherapy (SAC) in patients with stage III colon cancer (CC) aged 70-75 years, but not for older patients.
Major finding: MAC vs. SAC was associated with a survival benefit in patients aged 70-75 years (hazard ratio [HR] 0.81; P < .001), but not in those aged 76-80 (HR 0.90; P = .051), 81-85 (HR 0.97; P = .637), or 86-90+ (HR 0.95; P = .691) years.
Study details: This retrospective, age group-based study included 20,257 patients aged ≥70 years with stage III CC who received either SAC (n = 7334) or MAC (n = 12,923).
Disclosures: The study was supported by the Winship Research Informatics Shared Resource of Winship Cancer Institute of Emory University and US National Institutes of Health/National Cancer Institute. The authors declared no conflicts of interest.
Source: Khalil L et al. Survival outcomes of adjuvant chemotherapy in elderly patients with stage III colon cancer. Oncologist. 2022 (Jun 1). Doi: 10.1093/oncolo/oyac082
Key clinical point: Multi-agent adjuvant chemotherapy (MAC) offers a survival benefit over single-agent adjuvant chemotherapy (SAC) in patients with stage III colon cancer (CC) aged 70-75 years, but not for older patients.
Major finding: MAC vs. SAC was associated with a survival benefit in patients aged 70-75 years (hazard ratio [HR] 0.81; P < .001), but not in those aged 76-80 (HR 0.90; P = .051), 81-85 (HR 0.97; P = .637), or 86-90+ (HR 0.95; P = .691) years.
Study details: This retrospective, age group-based study included 20,257 patients aged ≥70 years with stage III CC who received either SAC (n = 7334) or MAC (n = 12,923).
Disclosures: The study was supported by the Winship Research Informatics Shared Resource of Winship Cancer Institute of Emory University and US National Institutes of Health/National Cancer Institute. The authors declared no conflicts of interest.
Source: Khalil L et al. Survival outcomes of adjuvant chemotherapy in elderly patients with stage III colon cancer. Oncologist. 2022 (Jun 1). Doi: 10.1093/oncolo/oyac082